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Abstract
Background: Use of multivitamin supplements during the pre-HAART era has been found to reduce viral load,
enhance immune response, and generally improve clinical outcomes among HIV-infected adults. However, immune
reconstitution is incomplete and significant mortality and opportunistic infections occur in spite of HAART. There is
insufficient research information on whether multivitamin supplementation may be beneficial as adjunct therapy for
HIV-infected individuals taking HAART. We propose to evaluate the efficacy of a single recommended daily
allowance (RDA) of micronutrients (including vitamins B-complex, C, and E) in slowing disease progression among
HIV-infected adults receiving HAART in Uganda.
Methods/Design: We are using a randomized, double-blind, placebo-controlled trial study design. Eligible patients
are HIV-positive adults aged at least 18 years, and are randomized to receive either a placebo; or multivitamins that
include a single RDA of the following vitamins: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 2.6 mcg B12, 18 mg niacin, 70 mg C,
10 mg E, and 0.4 mg folic acid. Participants are followed for up to 18 months with evaluations at baseline, 6, 12 and
18 months. The study is primarily powered to examine the effects on immune reconstitution, weight gain, and
quality of life. In addition, we will examine the effects on other secondary outcomes including the risks of
development of new or recurrent disease progression event, including all-cause mortality; ARV regimen change from
first- to second-line therapy; and other adverse events as indicated by incident peripheral neuropathy, severe anemia,
or diarrhea.
Discussions: The conduct of this trial provides an opportunity to evaluate the potential benefits of this affordable
adjunct therapy (multivitamin supplementation) among HIV-infected adults receiving HAART in a developing country
setting.
Trial registration: Clinical Trial Registration-URL: www.clinicaltrials.gov. Unique identifier: NCT01228578
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Background
Vitamins and minerals are important micronutrients for
optimal immune system function [1]. Nutrient deficien-
cies and their effects on immune function, disease
progression, and their markers of health have been
documented in HIV-infected persons [2,3]. Although the
widespread introduction of highly active antiretroviral
therapy (HAART) in most developing countries has
dramatically reduced morbidity and mortality among HIV-
positive individuals, under-nutrition that is common in
these settings, coupled with wasting that is characteristic of
HIV infection, may affect optimal immunologic response
after HAART initiation.
A number of studies conducted among HIV-infected
adults during the pre-HAART era, have shown that
multivitamin supplementation enhances immune recon-
stitution, reduces viral load, improves overall clinical
outcomes, and reduces mortality [4-6]. Among such
patients, multivitamins could slow disease progression
and prolong the time before HAART needs to be
initiated. But only a few interventional trials with small
sample sizes have explored multivitamin supplementa-
tion in relation to HIV progression during HAART. It is
unclear from these studies whether the micronutrient
supplementation-associated health benefits observed
during the pre-HAART era would also be observed
among HIV-infected patients on HAART; with some of
intervention studies suggesting beneficial treatment out-
comes [7-11], whereas others did not show any benefi-
cial treatment outcomes [12,13]. Sufficient data are
therefore lacking to evaluate whether micronutrient sup-
plementation during HAART has an impact on treat-
ments outcomes. A daily dose of multivitamins costs
less than 5 United States cents and adequate supply for
the duration of a year would cost less than $15. Identify-
ing whether such a low-cost intervention has an impact
on HIV disease progression among individuals on ART
is an important question to answer given the large po-
tential for improving quality of life and the cost-savings
that could result.
The primary aim of this trial is to determine whether
one recommended dietary allowance (RDA) dose of oral
multivitamin supplements (including vitamins B-complex,
C, and E) given daily for 18 months will: (1) improve im-
mune reconstitution (indicated by CD4 cell count); (2)
improve weight gain, and (3) improve quality of life.
Methods
Study design
This is a randomized, double-blind, placebo-controlled
trial. We are randomizing participants to receive daily
oral supplements in one of two experimental groups:
Group 1: multivitamins, including a single RDA of the
following vitamins: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 2.6
mcg B12, 18 mg niacin, 70 mg C, 10 mg E, and 0.4 mg
folic acid; or Group 2: placebo which consists of an in-
active pill of the same size, packaging and coloration as
the active multivitamin tablets.
Setting
The trial is being conducted at the Infectious Diseases
Institute (IDI), Makerere University College of Health
Sciences. IDI provides care and treatment for HIV
infected persons as one of its core functions; over
10,000 people receive care through the IDI HIV care
clinic, approximately 6,000 of which are on antiretro-
viral therapy (ART).
Recruitment and enrollment
Prior to physical contact with any patient by the study
staff, a designated clinical staff at the IDI HIV care clinic
conducts chart reviews of prospective HIV-positive
patients ahead of their scheduled clinic visit to deter-
mine their potential eligibility for HAART, or their dur-
ation of HAART use for those already on ARVs. This
information is made available to the trial Study Coordin-
ator, who uses the information to approach potential
trial participants identified upon arrival at the IDI HIV
care clinic for their next scheduled appointments. At
this time, the trial clinical staff informs the patient about
the trial and invites them for further eligibility screening
and possible enrollment into the trial. Prior to enroll-
ment, trial participation eligibility is documented, and
written informed consent sought from eligible patients.
Patients are provided with information on the objectives
of the study and confidentiality issues are emphasized.
At the end of this session, patients are given the oppor-
tunity to enroll in the trial at that time and are contin-
ued on the appropriate HIV care per Uganda’s standard
of care guidelines. Those who want to discuss their par-
ticipation in the trial with family members are given an
opportunity to do so and may enroll at their next sched-
uled clinic visit. Eligible subjects must meet the follow-
ing inclusion criteria: a) men or women aged >=18 years
old, b) HIV-positive, c) initiating anti-retroviral therapy
at the time of randomization or have been on HAART
for no longer than 6 months, d) have no intention of mi-
grating, or re-locating more than 20 km outside of the
IDI within the next 18 months after enrollment, e) agree
to allow home visit(s) and subsequent follow-up contacts
as part of the study, and f) provide written informed
consent.
Subjects with any of the following criteria are
excluded: a) Because iron and folic acid supplementation
are standard of care for pregnant women per the Ugan-
dan Ministry of Health standards, women with a positive
pregnancy test are excluded from participation in the
trial as we would not have adequate statistical power to
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examine this factor as an effect modifier; b) Individuals
who are very ill and unable to consent.
Randomization
Once a patient is deemed eligible and has provided con-
sent, they are randomized to receive the intervention or
placebo. Permuted block randomization was used, with a
block size of ten. Prior to initiation of the trial, a staff at
Harvard School of Public Health (HSPH) not associated
with implementation of the trial generated serial num-
bers from 1 through 400, and randomly assigned these
to A and B to indicate allocation to the intervention or
placebo groups using SAS version 9.0. Study regimen
bottles (manufactured on special order from Tishcon
Corp, Salisbury, MD), were then labeled with the serial
numbers only, but according to whether the specific
serial number was assigned to arm “A” or arm “B”. The
study regimen bottles were shipped to Uganda, but the
list showing the study arm to which each serial number
was assigned remains anonymous and is kept at HSPH
and not accessible to study staff in Uganda. At the time
of participant enrollment, the Study Pharmacist dis-
penses the assigned regimen bottles to the participant in
sequential order of enrollment. Participants are followed
for up to 18 months with evaluations at Baseline,
Months 3, 6, 12 and 18. The trial schema is illustrated in
Figure 1.
At all times during this trial, participants continue to
receive standard medical care according to Uganda’s
Ministry of Health (MoH) guidelines. The clinical study
staff provides the intervention regimen on a monthly
basis to participants as part of their routine medical
care. Home visits are performed for individuals who
miss their scheduled research study visits. An interim
Randomize to 
study arms  







Potential participants contacted 
and screened by Study 
Coordinator to confirm eligibility
Decline to 
participate 
Month 6 evaluation 
Month 12 evaluation 
Month 18 evaluation 
Month 6 evaluation 
Month 12 evaluation 
Month 18 evaluation 
Pre-eligibility assessment 
using HIV care clinic records
Clearly not eligible
Enroll consenting subjects 
(Target n=400)  
Month 3 evaluation Month 3 evaluation 
Figure 1 Trial Schema.
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history is conducted to assess participants’ general health
and well-being at baseline, months 3, 6, 12 and 18. At
the end of each clinic visit, participants receive the trial
regimen, instructions on the regimen use, and a follow-
up appointment. Table 1 shows the schedule of study
events for a typical patient.
Measurements
At baseline only, we administer a detailed background
information questionnaire to obtain socio-demographic
data, including age, parity, education, residence, employ-
ment status, socio-economic status variables, marital sta-
tus, and past/current use of tobacco, alcohol, and other
substances.
Clinical parameters
Patients undergo a full clinical examination and labora-
tory parameters including assessments of complete
blood counts (CBCs), CD4 counts, and assessments for
syphilis, malaria, intestinal parasites. Viral load is not
routinely conducted per Uganda’s standard of care.
Clinical information is recorded including: (1) a check-
list of symptoms – including fever, cough, diarrhea, and
anxiety or depression – in the previous month; (2) an
assessment of treatment compliance based on self-
report and pill count; and (3) anthropometric measure-
ments. In addition, study medical officers perform a
complete clinical examination. They code diagnoses
according to pre-defined criteria, record all diagnostic
tests performed, and document any medications pre-
scribed (e.g. antibiotics, anti-malarials, or changes in
HIV treatment). They also document whether partici-
pants have attended additional clinic visits outside of
their scheduled appointments, record reasons and diag-
noses related to these visits, as well as any hospitaliza-
tions that occur. We assess quality of life of participants
at baseline and every six months thereafter, using the
validated, culturally-adapted local language version of
the Medical Outcomes Survey-HIV [14].
In cases where patients miss their monthly appoint-
ments, a study nurse home visitor visits them at home
and encourages them to visit the clinic if their condi-
tion permits. For participants who travel out of the
study area, we maintain contact with relatives and
neighbors in the area of residence to continue monitor-
ing their health status. Although accurate cause-of-
death determinations are difficult (post-mortem exam-
ination is rarely done), we review hospital records to
identify events at or near a patient’s time of death for
those who die in the hospital. For those who die else-
where, we administer a verbal autopsy using a standard
form, which includes open- and closed-ended questions
to assess clinical parameters and treatments given near
the time of death. We will establish cause of death
based on consensus decision of two senior HIV clini-
cians at IDI using all data available.
Nutritional assessment
We obtain anthropometric and dietary information to
determine nutritional status at each study visit. Weight
and mid upper arm circumference (MUAC) are assessed
at baseline, month 3 and subsequently six monthly;
whereas height is measured at baseline only. Weight
and height will be used to calculate body mass index,
which together with MUAC will be used to assess nutri-
tional status. We calibrate instruments at regular inter-
vals; and trained study nurses perform anthropometric
measurements according to standard techniques, which
are standardized at baseline and at regular intervals
thereafter.
Dietary intake
At baseline and every six months, trained research
assistants administer a food frequency questionnaire
(FFQs); 24-hour and 7-day diet recalls are conducted at
all scheduled study visits. Based on our ongoing trials
of nutrition and infection in Tanzania, we are experi-
enced in performing both FFQs and 24-hour recalls in
similar HIV-infected populations. In particular, we have
spent considerable time in developing an adult FFQ in
Tanzania, and we adapted this questionnaire to this
study population in Uganda. This FFQ is comprised of
an 87-item food recipe list, and each participant is
asked to report the frequency and amount of their ‘typ-
ical’ consumption for each food item over the previous
month. In order to standardize the food quantities con-
sumed, we used commonly used household utensils in
Uganda as the portion sizes, to help participants esti-
mate the quantities of foods consumed. If a participant
reported to have eaten any food recipe listed, they were
asked to indicate the portion sizes consumed using the
commonly used household utensils. In a separate exer-
cise, each of the food recipe portion size was weighted,
and data on the weight (in grams) of each portion size
of each food recipe listed on the FFQ has been stored
in a database. During analysis, for each participant, the
amount of each item consumed will be multiplied by
its nutrient content (derived from nutrient composition
tables) and summed over all food items to obtain total
intakes for each type of nutrient.
Laboratory investigations
A blood specimen is taken from each participant at en-
rolment and every six months thereafter to measure
CD4 counts, CBCs - including hemoglobin levels, total
and differential white blood cell counts, hematocrit, bili-
rubin, creatinin and ALT as part of clinical standard of
care for all patients. Outside of standard of care
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Table 1 Schedule of events
ACTIVITY −30 to
−7 Days
BASELINE M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18
I. CASE REPORT FORMS
Pre-Eligibility Assessment X
Eligibility Confirmation & Informed Consent X
Enrollment & Randomization X
Contact Information X
Drug Regimen Refill of @ monthly clinic visits X X X X X X X X X X X X X X X X X X X
Background Questionnaire X
Health Assessment Questionnaire X X X X X
FFQ X X X X
QoL Questionnaire X X X X
Weight X X X X
II. LAB TESTS
CD4 X X X X X
CBC X X X X
Malaria Parasitemia X X X X
Helminth Infections X X X X
ALT X X X X
Urine Dipstick X X X X
III. SAMPLES FOR STORAGE
Lipid profile (HDL, LDL, Triglyceride) X X X X
Sample storage for cytokine Elisa (IL2, IL4, IL5, IL6, IL10, IL12, TNF-a,
IFN-γ)
X X X X





















measurements, one repeated measurement of CD4 cell
count is conducted at Month 3 to allow us to investigate
any acute changes in CD4 cell count in the participants
following randomization.
Testing for malaria parasitemia is assessed for all parti-
cipants every six months regardless of symptoms, and as
needed based on clinical indication. In addition, we as-
sess the presence of malaria parasites in the blood for all
participants through microscopic investigation of blood
smears at baseline, 6, 12 and 18 months. These samples
are microscopically analyzed by trained technicians at
the IDI laboratory.
In addition to the above, levels of the following lipids:
high density lipoproteins (HDL), low density lipoproteins
(LDL) and triglycerides will be assessed on the stored
serum specimens from 6, 12, and 18 month time points.
Vitamin B12 levels will also be assessed on stored
specimens on 15% of participants (n=60) to monitor
compliance at baseline and at six- and eighteen-month
follow-up. We will assess vitamin B12 using a com-
petitive magnetic separation assay on the Technico
Immuno-1 analyzer (Bayer, Tarytown, NY); this assay
has a day-to-day variability of less than 4.0% for con-
centrations of between 643 and 852 pg/mL. We also
store excess serum specimens from each blood draw at
−70 degrees centigrade, and will use them in ancillary
studies to examine mechanisms relating to multivita-
mins and additional outcomes, such as markers of
oxidative stress, cytokine proliferation, hepatitis, d4t
and serum vitamin levels that may be associated with
HIV disease progression.
Study outcomes
The primary outcomes in this trial are: (1) immune re-
constitution, defined as change in CD4 cell count; (2)
weight gain; and (3) change in quality of life, defined as
overall score on the Medical Outcomes Survey-HIV
(MOS-HIV) [14], and individual scores for general
health perceptions, physical functioning, pain, energy,
role functioning, social functioning, and mental health.
The secondary outcomes include: (1) development of a
new or recurrent disease progression event, including
all-cause death; (2) changes in antiretroviral treatment
defined as switching from first- to second-line therapy; and
(3) occurrence of adverse events, including peripheral
neuropathy, severe anemia, and diarrhea.
Statistical issues
Statistical power
We calculated powers for testing the efficacy of multivi-
tamins in relation to study outcomes over the 18-month
study period, with a sample size of 400, 200 in each
study arm, and Type I error rate α=0.05. For continuous
endpoints, we calculated power for two sample T test
based on the following equation (the example given here
is change in CD4 count):




where δ=|μ1-μ2| and μ1 and μ2 are the underlying






2 are the variances of
baseline and follow-up CD4 counts within a particu-
lar treatment arm, ρ is the correlation between baseline
and follow-up CD4 counts within a treatment arm over
time t, n = (400/2)*(1-F) and F is the proportion of
participants lost to follow-up over the study period,
and Ф is the cumulative distribution function of the
standard normal distribution.




2 and ρ were the same in the multivitamin
and placebo groups; we also assumed that the variance
of CD4 counts was the same at baseline and follow-up.
We calculated power over a range of assumptions for δ,
σd, ρ, and loss to follow-up during 18 months.
For the difference in CD4 count change over the study
period between treatment groups, we assumed a change,
δ = 40, 50, 60, and 70 cells/mm3 based on reported
effects of multivitamin supplements in an intervention
trial of patients on HAART for at least three months
[12]. For the standard deviation of CD4 counts at base-
line and follow-up, we assumed σ1 = σ2 = 175 and
225cells/mm3 based on reported values for several trial
populations receiving HAART in Brazil and the United
States [12,15]. We assumed correlations between base-
line and follow-up values of CD4 counts based on the
dataset available from our Tanzanian intervention trial
[5]; ρ = 0.5, 0.6, and 0.7. For lost to follow-up (F), we
used a proportion of 0.10 based on our experience in
rigorously conducted randomized trials in Tanzania and
Uganda. Table 2 shows estimated power across these
various assumptions. There is adequate power to exam-
ine the effect of the interventions on immune re-consti-
tution. For example, estimated power assuming δ = 40,
σ1 = σ2 = 175, and ρ = 0.7 was 80%; as expected, the
estimated power was higher with bigger mean difference
in CD4 change (Table 2).
Similarly, we calculated power estimates for multivita-
min effects on weight change over the study period
(Table 3). Assumptions for the mean difference in weight
change between treatment and placebo groups (δ=2, 2.5,
3, and 3.5), as well as standard deviations at baseline and
follow-up, are based on studies of HAART initiation that
reported weight gain over one year in several African
countries [16-18]. Although reported values are some-
what variable (ranging from 3 to 9kg), we believe our
assumptions are conservative, representing a range of
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values that are generally smaller than those reported for
HAART-related weight gain.
We also calculated power for detecting quality of life
changes in the proposed MOS-HIV mental health sum-
mary score. Based on a recent study of quality of life in
rural Uganda [14], we evaluated a range of parameter
estimates: δ = 4, 6, and 8 points and σ1 = σ2 = 7 and 11;
again, we assumed ρ = 0.5, 0.6, and 0.7. This range of
score differences assumes less than half of the score im-
provement associated with HAART over one year of
treatment in the Ugandan study (mean difference=+14.2
points on the same mental health summary score) [19].
Furthermore, we assume a 10-20% increase in scores
from those reported at baseline in Uganda, which is well
within the range of multivitamin effects observed in our
Tanzanian trials [5]. Overall, power was estimated at
>90% for our proposed study across the range of
assumptions we investigated; most estimates were >99%.
Planned statistical analysis
For the primary outcomes, we will use intention-to-treat
analyses for all primary outcomes. We will employ
mixed models to evaluate changes over time in CD4
count, weight gain, and quality of life in relation to
assigned treatment group. These models accommodate
repeated measures of the outcome, and account for
baseline levels as well as concomitant risk factors for the
outcome [20].
To evaluate the occurrence of disease progression or
mortality, we will use the chi-squared test to compare
the proportion of participants who experience these out-
comes in the two treatment groups. To assess whether
treatment prolongs the time for attaining this endpoint,
the log-rank test will be used and Kaplan-Meier curves
will be plotted for each treatment group. For adverse
drug outcomes (i.e. occurrence of peripheral neuropathy,
severe anemia, and diarrhea), we must account for the
possibility that participants may experience multiple epi-
sodes over the study period. Thus, we will use log-
binomial models for repeated outcomes to examine the
treatment effect on these outcomes.
Ethical approval
The trial protocol was approved by the Scientific Review
Committee of the Infectious Diseases Institute at Makerere
University College of Health Sciences; and the Institutional




Standard deviation of CD4
counts at baseline and follow-up
(σ1 = σ2, in cells/mm
3)
Correlation of CD4 counts between
baseline and follow-up (ρ)
0.5 0.6 0.7
40 175 58 68 80
225 39 47 59
50 175 77 86 94
225 56 66 78
60 175 90 95 99
225 72 81 90
70 175 97 99 >99
225 84 91 97




Standard deviation of weight at
baseline and follow-up
(σ1 = σ2, in cells/mm
3)
Correlation of weight between
baseline and follow-up (ρ)
0.5 0.6 0.7
2 9 56 66 78
11 41 49 61
2.5 9 75 88 96
11 58 74 86
3 9 88 94 98
11 74 82 92
3.5 9 96 98 >99
11 86 92 97
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Review Boards of Harvard School of Public Health and that
of Makerere University School of Public Health.
Discussion
The provision of HAART has significantly decreased
HIV-associated morbidity and mortality over the last
fifteen years, but despite the substantial benefits of
HAART, immune reconstitution may not be complete
and the risk of opportunistic infection and death can be
high in less developed countries, especially in the first
few following treatment initiation. Multivitamins are key
factors in maintaining immune function and neutralizing
oxidative stress, and among individuals not receiving
HAART, but sufficient research data are lacking on
whether micronutrient supplementation during HAART
has an impact on treatments outcomes [21]. This is
especially important on the potential benefits of this
affordable adjunct therapy in developing country set-
tings. Since the widespread introduction of HAART,
only a few, mainly small, intervention trials have
explored multivitamin supplementation in relation to
HIV progression. Two non-randomized studies of anti-
oxidant vitamins showed no effects on plasma viral load,
although one noted a significant increase in glutathione
and glutathione peroxidase [8] and the other identified
more pronounced metabolic disturbances in patients
with lipoatrophy and hyperlactemia [7]. In a randomized
trial of daily vitamin E supplementation [9,10], CD4
counts, the ratio of CD4 to CD8 cells, and plasma viral
load remained similar after six months in the treatment
versus placebo groups, but supplementation was asso-
ciated with increased lymphocyte viability. In another
trial of daily vitamin A, C, and E supplementation,
the supplementation group had significantly elevated
concentrations of catalase and superoxide dismutase
compared to placebo; still, increases in CD4 count were
non-significant in the supplementation group [11]. In a
small randomized trial (n=40) of multivitamin supple-
ments given twice daily for three months, those who
received supplements had significantly higher absolute
CD4 counts and greater mean increases in CD4 count
from baseline (p=0.01) [12]. Another small trial (n=30)
found that multivitamins (including vitamin E) improved
asymptomatic stable chronic hyperlactatemia in HIV-
infected patients on long-term HAART [13].
A recently completed trial from Tanzania com-
pared the effects of high doses of supplements
including vitamin B complex, vitamin C, and vitamin
E with standard doses at the recommended dietary
allowance level [22]. High-dose supplementation
had no effect on several key measures that reveal
HIV disease progression—CD4 count, plasma viral
load, body mass index, or hemoglobin level concen-
tration—and did not reduce death or disease
progression risks for HIV-infected patients. This
study does not rule out the possibility that the high-
and standard-dose regimens are equally efficacious.
Placebo control trials, such as this ongoing trial in
Uganda, are necessary to examine the overall benefit
of supplements compared to standard of care, which
does not include micronutrient supplements to
patients on HAART in many settings. Our trial provides
an opportunity to evaluate the safety and efficacy of a single
RDA of micronutrients in improving clinical and immuno-
logical outcomes, and quality of life among HIV-infected
adults receiving HAART in a developing country setting.
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